Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

The first ever US-approved biosimilar approved is Zarxio, Sandoz's version of Amgen's Neupogen (filgrastim) white blood cell stimulator. However it has captured only around 7% of the market ...

Biosimilars, copies of off-patent biopharmaceuticals ... a pegylated form of the granulocyte colony-stimulating factor analog filgrastim, which mitigates the negative effects of chemotherapy ...

IMS Health anticipates that biosimilars could save health systems ... and Sandoz's Zarzio (filgrastim-sndz), which are near copies of J&J's Remicade inflammatory diseases drug and Amgen's Neupogen ...

Health Canada has granted approval to Nora Pharma for the commercialisation of its first biosimilar product, Niopeg (a pegylated form of filgrastim). The Niopeg is comparable to the reference ...

Amneal said it has five biosimilars in the pipeline. Three others are already available for treating cancer: Releuko (filgrastim-ayow) and Fylnetra (pegfilgrastim-pbbk), both developed in ...